Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes

NCT01511172 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of adding liraglutide to metformin compared to using liraglutide or metformin alone, or metformin with a sulphonylurea, in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 145 people

Who can join Ages 18–70 · all sexes

Timeline Started 2002-08 · est. completion 2002-12

Where 41 sites · Australia, Austria, Czechia, Denmark, France, Germany, Poland, United Kingdom

What this study is testing ClinicalTrials.gov NCT01511172 ↗

Description as written by the study sponsor.

This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effect on glycemic control of NNC 90-1170 (liraglutide) added to metformin compared to metformin given alone in subjects with type 2 diabetes previously treated with OHAs (oral hypoglycaemic agents).

Treatments tested

liraglutide Drug

Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
metformin Drug

1000 mg daily, administered orally
placebo Drug

Metformin placebo administered orally. 1000 mg daily
placebo Drug

NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
glimepiride Drug

Individually adjusted dose, administered orally

Main thing measured	Fasting plasma/serum glucose
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01511172 ↗